Analysts Expect AnaptysBio Inc (NASDAQ:ANAB) to Post -$1.17 EPS

Equities research analysts forecast that AnaptysBio Inc (NASDAQ:ANAB) will report ($1.17) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for AnaptysBio’s earnings, with the lowest EPS estimate coming in at ($1.47) and the highest estimate coming in at ($0.77). AnaptysBio reported earnings per share of ($0.66) in the same quarter last year, which suggests a negative year over year growth rate of 77.3%. The company is scheduled to report its next quarterly earnings report on Thursday, November 14th.

Zacks Investment Research’s earnings per share averages are an average based on a survey of analysts that that provide coverage for AnaptysBio.

AnaptysBio (NASDAQ:ANAB) last issued its earnings results on Thursday, August 8th. The biotechnology company reported ($0.89) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.97) by $0.08. The business had revenue of $5.00 million during the quarter. AnaptysBio’s revenue for the quarter was up 4900.0% compared to the same quarter last year. During the same quarter last year, the company earned ($0.57) EPS.

A number of equities analysts have recently weighed in on ANAB shares. BidaskClub upgraded AnaptysBio from a “strong sell” rating to a “sell” rating in a report on Friday. Zacks Investment Research upgraded AnaptysBio from a “sell” rating to a “hold” rating in a report on Tuesday, October 15th. ValuEngine upgraded AnaptysBio from a “hold” rating to a “buy” rating in a report on Friday, August 16th. Cantor Fitzgerald set a $140.00 target price on AnaptysBio and gave the company a “buy” rating in a report on Tuesday, August 20th. Finally, Wedbush reiterated an “outperform” rating on shares of AnaptysBio in a report on Tuesday, October 1st. One analyst has rated the stock with a sell rating, three have issued a hold rating and seven have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $99.63.

A number of large investors have recently added to or reduced their stakes in ANAB. Invesco Ltd. increased its holdings in AnaptysBio by 25,030.8% in the second quarter. Invesco Ltd. now owns 1,097,462 shares of the biotechnology company’s stock worth $61,919,000 after buying an additional 1,093,095 shares during the last quarter. BlackRock Inc. increased its holdings in AnaptysBio by 13.4% in the second quarter. BlackRock Inc. now owns 2,050,390 shares of the biotechnology company’s stock worth $115,681,000 after buying an additional 242,187 shares during the last quarter. Price T Rowe Associates Inc. MD increased its holdings in AnaptysBio by 18.6% in the second quarter. Price T Rowe Associates Inc. MD now owns 937,273 shares of the biotechnology company’s stock worth $52,881,000 after buying an additional 147,292 shares during the last quarter. Nuveen Asset Management LLC acquired a new position in AnaptysBio in the second quarter worth approximately $5,606,000. Finally, Sphera Funds Management LTD. acquired a new position in AnaptysBio in the first quarter worth approximately $5,114,000.

Shares of ANAB traded down $0.25 during trading hours on Thursday, reaching $37.04. The company’s stock had a trading volume of 231,808 shares, compared to its average volume of 454,962. The firm has a market cap of $1.01 billion, a price-to-earnings ratio of -14.82 and a beta of 1.50. AnaptysBio has a 1-year low of $29.43 and a 1-year high of $87.49. The company has a 50 day moving average of $38.54 and a two-hundred day moving average of $57.60.

About AnaptysBio

AnaptysBio, Inc, a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The company's products include Etokimab, an anti-interleukin (IL)-33 program for the treatment of atopic dermatitis, eosinophilic asthma, and chronic rhinosinusitis with nasal polyps; ANB019, an anti-IL-36 receptor program for generalized pustular psoriasis and palmo-plantar pustular psoriasis; and anti-inflammatory checkpoint modulators for inflammatory diseases.

See Also: Buyback For Investors Defined

Get a free copy of the Zacks research report on AnaptysBio (ANAB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for AnaptysBio (NASDAQ:ANAB)

Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.